Trial Profile

Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Patients With Relapsed/Refractory CD30 Positive T-cell Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brentuximab vedotin (Primary) ; Pembrolizumab (Primary)
Indications Anaplastic large cell lymphoma; Cutaneous T-cell lymphoma; Extranodal NK-T-cell lymphoma; Mycosis fungoides; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome; T-cell lymphoma
Focus Therapeutic Use

Most Recent Events

03 Mar 2025 Planned number of patients changed from 43 to 32.
11 Oct 2023 Planned initiation date changed from 15 Aug 2023 to 1 Oct 2023.
10 Jul 2023 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 Feb 2023 to 15 Aug 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com